Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease. Clin Exp Rheumatol. 2019 Jul-Aug; 37 Suppl 119(4):115-124.